BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/26/2024 10:21:34 AM | Browse: 205 | Download: 866
 |
Received |
|
2024-06-07 06:20 |
|
Peer-Review Started |
|
2024-06-07 06:20 |
|
First Decision by Editorial Office Director |
|
2024-07-30 06:44 |
|
Return for Revision |
|
2024-07-30 06:44 |
|
Revised |
|
2024-08-29 07:45 |
|
Publication Fee Transferred |
|
2024-10-22 00:33 |
|
Second Decision by Editor |
|
2024-10-08 23:58 |
 |
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2024-10-16 07:49 |
|
Articles in Press |
|
2024-10-16 07:49 |
|
Edit the Manuscript by Language Editor |
|
2024-11-04 07:12 |
|
Typeset the Manuscript |
|
2024-11-06 08:06 |
|
Publish the Manuscript Online |
|
2024-11-26 10:21 |
| ISSN |
1948-0210 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Basic Study |
| Article Title |
Exosome-based strategy against colon cancer using small interfering RNA-loaded vesicles targeting soluble a proliferation-inducing ligand
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Hyung-Jin Kim, Do Sang Lee, Jung Hyun Park, Ha-Eun Hong, Ho Joong Choi, Ok-Hee Kim and Say-June Kim |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Research Foundation of Korea |
NRF-2018R1D1A1B07047144 |
|
| Corresponding Author |
Say-June Kim, PhD, Professor, Department of Surgery, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, 222, Banpo-daero, Seocho-gu, Seoul 06591, South Korea. sayjunekim@catholic.ac.kr |
| Key Words |
Colon cancer; Drug delivery system; Exosome; Soluble a proliferation-inducing ligand; Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1; Targeted therapy |
| Core Tip |
This study investigates the potential of bioengineered exosomes (Exs), specifically small interfering peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 RNA-loaded soluble a proliferation-inducing ligand-targeted Exs, in treating colon cancer. By targeting soluble A proliferation-inducing ligand and delivering small interfering peptidyl-prolyl cis-trans isomerase NIMA-interacting 1, these modified Exs demonstrated superior efficacy in inhibiting tumor growth and epithelial-mesenchymal transition compared to standard Ex treatments. The findings highlight the promise of the novel targeted Exs, offering insights into the enhanced targetability and anticancer effectiveness of Ex-based therapies in oncological applications. |
| Publish Date |
2024-11-26 10:21 |
| Citation |
Kim HJ, Lee DS, Park JH, Hong HE, Choi HJ, Kim OH, Kim SJ. Exosome-based strategy against colon cancer using small interfering RNA-loaded vesicles targeting soluble a proliferation-inducing ligand. World J Stem Cells 2024; 16(11): 956-973 |
| URL |
https://www.wjgnet.com/1948-0210/full/v16/i11/956.htm |
| DOI |
https://dx.doi.org/10.4252/wjsc.v16.i11.956 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
